Back

Rationale behind development of novel drugs for atrial arrhythmias

19 March 2019 (11:36 - 11:54)
Organised by:
Congress Presentation Part of: Critical appraisal of antiarrhythmic drug therapy - The science behind trial-and-error Arrhythmias EHRA Premium Access EHRA 2019

About the speaker

Photo
Professor Jordi Heijman

Medical University of Graz, Graz (Austria)

4 More presentations in this session

Presentation thumbnail
The trials-and-errors of antiarrhythmic drug therapy
Professor J. Camm (London, GB)
Slides Video
Presentation thumbnail
Genetic basis for tailored drug therapy for ventricular arrhythmias
Associate Professor C. Remme (Amsterdam, NL)
Presentation thumbnail
Antiarrhythmic drugs - What, why, when to whom
Professor G. Dan (Bucharest, RO)
Presentation thumbnail
Panel discussion
Video

Access the full session

Session thumbnail
Critical appraisal of antiarrhythmic drug therapy - The science behind trial-and-error

The Event

Event poster

EHRA 2019

19 March 2019 11:36 CET
You may be interested in
thumbnail
Congress Session
EHRA Consensus Paper on Antiarrhythmic Drugs (AADs)
30 March 2025
thumbnail
Congress Presentation
Atrial tissue engineering using conditionally immortalized human myocytes: establishing matured and geometrically-defined 3D models of atrial arrhythmias
12 April 2026
thumbnail
Congress Presentation
Atrial arrhythmia associated with cdk4/6 inhibitor use in patients with hormone receptor-positive / HER2-negative breast cancer
20 June 2025
thumbnail
Congress Presentation
Unravelling the signaling pathway downstream of the neurokinin receptor in atrium: discovering novel anti-arrhythmic targets for treatment of atrial fibrillation
28 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources